Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 13

recruiting
3 968
countries
28
conditions
2 103

439 trials match your criteria

Study Comparing Givinostat and Hydroxyurea for Patients with High-Risk Polycythemia Vera

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carbasalate Calcium

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone

Neoplasm+5

Recruiting

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Study on the Safety and Effectiveness of BGB-11417 Alone and with Dexamethasone, Carfilzomib, Daratumumab, or Pomalidomide for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib

Study Comparing Pirtobrutinib and Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tocilizumab

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib

Ovarian cancer

Recruiting

Study Comparing Avutometinib and Defactinib with Other Treatments for Patients with Recurrent Low-Grade Serous Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Study on the Safety and Effects of Divarasib with Pembrolizumab and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide

Study of Palbociclib and Fulvestrant for Women with Advanced Breast Cancer After Previous CDK4/6 Inhibitor and Hormonal Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.